Futuximab/modotuximab

Drug Profile

Futuximab/modotuximab

Alternative Names: 1024; 992; 992/1024; Anti epidermal growth factor receptor monoclonal antibody - Symphogen; Anti-EGFR-monoclonal-antibody-Symphogen; DS 992/DS 1024; Modotuximab/futuximab; Sym-004

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Symphogen
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Glioma
  • Phase I Non-small cell lung cancer; Oesophageal cancer
  • No development reported Head and neck cancer

Most Recent Events

  • 23 Feb 2017 Symphogen withdraws prior to enrolment a phase I/II trial in Non-small cell lung cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02924233)
  • 18 Jan 2017 Symphogen withdraws a phase II trial prior to enrolment due to a business decision in Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain, USA and Italy (IV) (NCT02965417)
  • 14 Nov 2016 Symphogen plans a phase II trial for Colorectal cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Italy and Spain (IV) (NCT02965417)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top